Welcome
Since we opened in 1978, we have focused on one goal, to make the highest quality cancer care accessible to you.
As a private practice with nearly 50% of Maine’s medical oncologists and hematologists on our team, we’re pleased to introduce a new name that reflects our history of excellence.
Learn more about the New England Cancer Specialists team
Latest Cancer News
Palbociclib/Letrozole Improves Outcomes of Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer
(02-27-2015)
The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) delayed the time to cancer... Continue Reading
FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer (02-26-2015)
The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted for the treatment... Continue Reading
Farydak® Approval Provides Another Treatment Option for Patients With Multiple Myeloma (02-25-2015)
Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat) in combination with Velcade® and dexamethasone for the treatment of patients with multiple... Continue Reading
The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) delayed the time to cancer... Continue Reading
FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer (02-26-2015)
The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted for the treatment... Continue Reading
Farydak® Approval Provides Another Treatment Option for Patients With Multiple Myeloma (02-25-2015)
Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat) in combination with Velcade® and dexamethasone for the treatment of patients with multiple... Continue Reading
More Cancer News
Types of Cancer
More Cancer Types
Locations
| Scarborough Office 100 Campus Drive, Suite 108 Scarborough, Maine 04074-9308 (207) 396-7600 Fax (207) 396-7610 |
Brunswick Office 81 Medical Center Drive Suite 1300G Brunswick, ME 04011 (207) 729-1148 Fax (207)729-2789 |
| Biddeford Office 26 West Cole Road Biddeford, Maine 04005-9407 (207) 282-0448 Fax (207)286-9126 |
Sanford Office 27 Industrial Avenue Sanford, ME 04073 (207)490-7777 Fax (207) 490-7779 |